
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.600 | 79.970 | 78.370 |
Shares | 98.400 | 98.400 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.071 | 19.596 |
Price to Book | 3.817 | 2.575 |
Price to Sales | 2.404 | 1.729 |
Price to Cash Flow | 14.990 | 13.185 |
Dividend Yield | 2.013 | 1.862 |
5 Years Earnings Growth | 8.470 | 11.274 |
Name | Net % | Category Average |
---|---|---|
Industrials | 52.310 | 39.590 |
Healthcare | 12.310 | 14.634 |
Financial Services | 12.300 | 7.032 |
Technology | 7.040 | 11.424 |
Consumer Defensive | 6.960 | 5.005 |
Consumer Cyclical | 5.030 | 7.437 |
Real Estate | 2.200 | 10.547 |
Communication Services | 1.860 | 5.261 |
Number of long holdings: 30
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Atlas Copco B | SE0017486897 | 7.64 | 138.9 | +0.36% | |
AstraZeneca | GB0009895292 | 7.06 | 10,772.0 | -0.09% | |
ABB | CH0012221716 | 6.01 | 47.27 | +0.06% | |
EQT AB | SE0012853455 | 5.59 | 284.50 | +1.39% | |
AddLife | SE0014401378 | 5.05 | 193.00 | +0.63% | |
Epiroc A | SE0015658109 | 4.78 | 215.90 | -0.64% | |
Hexagon B | SE0015961909 | 4.69 | 97.17 | -0.30% | |
Essity B | SE0009922164 | 4.39 | 271.30 | -1.09% | |
Addtech | SE0014781795 | 3.84 | 337.20 | -0.65% | |
Lifco publ AB | SE0015949201 | 3.54 | 400.40 | -1.28% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
NO0010923899 | 22.56B | -1.30 | 7.10 | 8.84 | ||
NO0010923915 | 22.56B | -1.40 | 6.84 | 8.57 | ||
NO0010923931 | 22.56B | -1.60 | 6.31 | 7.85 | ||
NO0010923956 | 22.56B | -1.30 | 7.10 | 8.72 | ||
NO0010923824 | 24.31B | -12.72 | 4.13 | 9.25 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review